↓ Skip to main content

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

Overview of attention for article published in BMC Cancer, November 2011
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
59 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Published in
BMC Cancer, November 2011
DOI 10.1186/1471-2407-11-505
Pubmed ID
Authors

Charlotte M Huijts, Saskia J Santegoets, Alfons J van den Eertwegh, Laura S Pijpers, John B Haanen, Tanja D de Gruijl, Henk M Verheul, Hans J van der Vliet

Abstract

For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to prolong progression free survival. Intriguingly, inhibition of mTOR also promotes expansion of immunosuppressive regulatory T cells (Tregs) that can inhibit anti-tumor immune responses in a clinically relevant way in various tumor types including RCC. This study intends to investigate whether the antitumor efficacy of everolimus can be increased by preventing the detrimental everolimus induced expansion of Tregs using a metronomic schedule of cyclophosphamide.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 2%
Unknown 58 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 22%
Student > Ph. D. Student 10 17%
Student > Bachelor 6 10%
Student > Master 6 10%
Student > Doctoral Student 5 8%
Other 7 12%
Unknown 12 20%
Readers by discipline Count As %
Medicine and Dentistry 24 41%
Agricultural and Biological Sciences 7 12%
Immunology and Microbiology 5 8%
Nursing and Health Professions 3 5%
Biochemistry, Genetics and Molecular Biology 2 3%
Other 5 8%
Unknown 13 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2011.
All research outputs
#3,557,743
of 5,039,474 outputs
Outputs from BMC Cancer
#1,762
of 2,818 outputs
Outputs of similar age
#146,393
of 233,918 outputs
Outputs of similar age from BMC Cancer
#56
of 84 outputs
Altmetric has tracked 5,039,474 research outputs across all sources so far. This one is in the 16th percentile – i.e., 16% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,818 research outputs from this source. They receive a mean Attention Score of 2.3. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,918 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 84 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.